PMC3862314_01
Technetium-99m skeletal scintigraphy of (A) multiple bone metastases 4 months after primary treatment and (B) 41 months after the last administration of pamidronate. Arrows indicate the bone metastases.
gr1.jpg
PMC3862314_01_gr1.jpg
f0005
Skeletal scintigraphy revealed multiple pelvic bone metastases (Fig. 1A) while magnetic resonance imaging (MRI) revealed a tumor that was not observed at the time of completion of the primary treatment (Fig. 2B). Follow-up skeletal scintigraphy showed no abnormal lesions, and the serum levels of ALP and NTx declined to the normal range 41 months after the last administration of pamidronate (Fig. 1B).